Introduction In recent years, the incidence of prostate cancer (PCa) has been at the forefront of male cancer incidence and shows an increasing trend year by year [ 1 , 2 ], which also makes prostate cancer the fifth leading cause of cancer-related death in men [ 3 ].
← all excerpts
EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer.
1
—
—